目的探讨慢性鼻窦炎伴鼻息肉(chronic rhinosinusitis with nasal polyps,CRSwNP)实施外周血嗜酸粒细胞(eosinophil,EOS)百分比联合鼻窦CT评分诊断的价值。方法选取黔东南苗族侗族自治州人民医院2023年1—12月诊断的80例CRSwNP患者,以...目的探讨慢性鼻窦炎伴鼻息肉(chronic rhinosinusitis with nasal polyps,CRSwNP)实施外周血嗜酸粒细胞(eosinophil,EOS)百分比联合鼻窦CT评分诊断的价值。方法选取黔东南苗族侗族自治州人民医院2023年1—12月诊断的80例CRSwNP患者,以病理组织EOS计数为准,分为嗜酸粒细胞性慢性鼻窦炎伴鼻息肉(eosinophilic chronic rhinosinusitis with nasal polyps,ECRSwNP)组(38例)和非嗜酸粒细胞性慢性鼻窦炎伴鼻息肉(non-eosinophilic chronic rhinosinusitis with nasal polyps,Non-ECRSwNP)组(42例),观察比较2组患者的外周血EOS个数、百分比、绝对值,鼻窦CT嗅裂、筛窦、上颌窦总评分与筛窦评分/上颌窦评分(E/M)比值。结果ECRSwNP组外周血EOS个数(95.28±27.02)个、EOS百分比(8.63±1.25)%、EOS绝对值(0.61±0.12)×10^(9)/L,鼻窦CT嗅裂总评分(3.13±0.76)分、筛窦总评分(6.67±1.32)分、E/M比值(3.34±0.71),均高于Non-ECRSwNP组的(66.19±18.64)个、(3.04±0.96)%、(0.25±0.07)×10^(9)/L、(1.94±0.25)分、(4.51±1.06)分、(1.58±0.46),鼻窦CT上颌窦总评分(1.87±0.36)分比Non-ECRSwNP组的(2.97±0.54)分更低(P<0.05);回归分析显示,CRSwNP的主要影响因素包括外周血EOS个数、EOS百分比及鼻窦CT中的嗅裂总评分、筛窦总评分(P=0.005、0.007、0.012、0.018),外周血EOS百分比、E/M比值是预测ECRSwNP的主要影响因素(P=0.004、0.035)。结论外周血EOS百分比联合鼻窦CT评分可有效鉴别诊断ECRSwNP与Non-ECRSwNP。展开更多
慢性粒细胞白血病(CML)是一种发生在多功能造血干细胞的主要涉及髓系的恶性骨髓增殖性肿瘤,简称慢粒。慢粒治疗应着重于慢性期早期,尽快获得细胞遗传学以及分子生物学水平的缓解,避免疾病转化,进入进展期的患者常常预后不佳。慢粒慢性...慢性粒细胞白血病(CML)是一种发生在多功能造血干细胞的主要涉及髓系的恶性骨髓增殖性肿瘤,简称慢粒。慢粒治疗应着重于慢性期早期,尽快获得细胞遗传学以及分子生物学水平的缓解,避免疾病转化,进入进展期的患者常常预后不佳。慢粒慢性期患者治疗首选酪氨酸激酶抑制剂(TKI),TKI极大地改善了疾病地整体预后,使绝大多数患者生存期接近正常人。本文主要对TKI在CML的应用进展进行综述。CML is a malignant myeloproliferative tumor occurring in multifunctional hematopoietic stem cells, mainly involving the myeloid lineage. The treatment of CML should focus on the early chronic phase, avoid disease transformation, obtain cytogenetic and molecular remission as soon as possible. Once in the progressive phase, the patients may have a poor prognosis. TKI is the first choice for treatment in chronic patients. With the development of TKI, the course of CML has changed greatly, and the survival of most patients is close to normal people. This paper mainly reviews the application progress of TKI in CML.展开更多
文摘目的探讨慢性鼻窦炎伴鼻息肉(chronic rhinosinusitis with nasal polyps,CRSwNP)实施外周血嗜酸粒细胞(eosinophil,EOS)百分比联合鼻窦CT评分诊断的价值。方法选取黔东南苗族侗族自治州人民医院2023年1—12月诊断的80例CRSwNP患者,以病理组织EOS计数为准,分为嗜酸粒细胞性慢性鼻窦炎伴鼻息肉(eosinophilic chronic rhinosinusitis with nasal polyps,ECRSwNP)组(38例)和非嗜酸粒细胞性慢性鼻窦炎伴鼻息肉(non-eosinophilic chronic rhinosinusitis with nasal polyps,Non-ECRSwNP)组(42例),观察比较2组患者的外周血EOS个数、百分比、绝对值,鼻窦CT嗅裂、筛窦、上颌窦总评分与筛窦评分/上颌窦评分(E/M)比值。结果ECRSwNP组外周血EOS个数(95.28±27.02)个、EOS百分比(8.63±1.25)%、EOS绝对值(0.61±0.12)×10^(9)/L,鼻窦CT嗅裂总评分(3.13±0.76)分、筛窦总评分(6.67±1.32)分、E/M比值(3.34±0.71),均高于Non-ECRSwNP组的(66.19±18.64)个、(3.04±0.96)%、(0.25±0.07)×10^(9)/L、(1.94±0.25)分、(4.51±1.06)分、(1.58±0.46),鼻窦CT上颌窦总评分(1.87±0.36)分比Non-ECRSwNP组的(2.97±0.54)分更低(P<0.05);回归分析显示,CRSwNP的主要影响因素包括外周血EOS个数、EOS百分比及鼻窦CT中的嗅裂总评分、筛窦总评分(P=0.005、0.007、0.012、0.018),外周血EOS百分比、E/M比值是预测ECRSwNP的主要影响因素(P=0.004、0.035)。结论外周血EOS百分比联合鼻窦CT评分可有效鉴别诊断ECRSwNP与Non-ECRSwNP。
文摘慢性粒细胞白血病(CML)是一种发生在多功能造血干细胞的主要涉及髓系的恶性骨髓增殖性肿瘤,简称慢粒。慢粒治疗应着重于慢性期早期,尽快获得细胞遗传学以及分子生物学水平的缓解,避免疾病转化,进入进展期的患者常常预后不佳。慢粒慢性期患者治疗首选酪氨酸激酶抑制剂(TKI),TKI极大地改善了疾病地整体预后,使绝大多数患者生存期接近正常人。本文主要对TKI在CML的应用进展进行综述。CML is a malignant myeloproliferative tumor occurring in multifunctional hematopoietic stem cells, mainly involving the myeloid lineage. The treatment of CML should focus on the early chronic phase, avoid disease transformation, obtain cytogenetic and molecular remission as soon as possible. Once in the progressive phase, the patients may have a poor prognosis. TKI is the first choice for treatment in chronic patients. With the development of TKI, the course of CML has changed greatly, and the survival of most patients is close to normal people. This paper mainly reviews the application progress of TKI in CML.
